Analysis of Gingival Crevicular Fluid

Analysis of Gingival Crevicular Fluid IL-1β, IL-10, IL-36γ Cytokine Levels in Gingivitis and Periodontitis Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05325905

Acronym

GCF

Enrollment

Registered

2022-04-13

Start date

2014-10-31

Completion date

2017-01-31

Last updated

2022-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Diseases

Keywords

pathogenesis, Gingival crevicular fluid, cytokine

Brief summary

The purpose of this study was to investigate and compare GCF interleukin-1β (IL-1β), interleukin-10 (IL-10), interleukin-36γ (IL-36γ) levels in patients with healthy (H), gingivitis (G) and chronic periodontitis (CP) status.

Detailed description

Gingival crevicular fluid (GCF) is formed when fluid exudes from the vessels of the microcirculation into the inflamed periodontal tissue and into the sulcus or pocket. As the fluid traverses the inflamed tissue, it is thought to pick up enzymes and other molecules that participate in the destructive process, as well as products of cell and tissue degradation. Efforts to develop diagnostic tests based on host factors have been focused almost entirely on analysis of GCF. The purpose of this study was to investigate and compare GCF interleukin-1β (IL-1β), interleukin-10 (IL-10), interleukin-36γ (IL-36γ) levels in patients with healthy (H), gingivitis (G) and chronic periodontitis (CP) status. Systemically healthy and non-smokers 80 participants (30 males and 50 females) who were selected from among admitting to Dentistry Faculty of Selcuk University were included in this study. Clinical periodontal parameters were recorded and GCF samples were obtained. Samples were stored in -80 ˚C until analysis with Enzyme-Linked ImmunoSorbent Assay (ELISA).

Interventions

DIAGNOSTIC_TESTGingival crevicular fluid sampling

GCF sampling and clinical periodontal measurements were performed

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Systemically healthy * non-smokers, * presence of at least 20 teeth in the mouth

Exclusion criteria

* receiving periodontal therapy in the last 6 months; * receiving antibiotics or anti-inflammatory drugs in the last 6 months; * currently pregnant or breastfeeding * using a removable partial denture and removable or fixed orthodontic appliances.

Design outcomes

Primary

Measure	Time frame	Description
Interleukin-36γ (IL-36γ) levels in GCF	Baseline	GCF samples were obtained from one interproximal site in each quadrant

Secondary

Measure	Time frame	Description
Clinical attachment level (CAL)	Baseline	CAL; from six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual locations) of each tooth other than third molars.
Bleeding on Probing (BoP)	Baseline	BoP, from six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual locations) of each tooth other than third molars
Probing depth (PD)	Baseline	PD; from six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual locations) of each tooth other than third molars.
Plaque Index (PI)	Baseline	PI; from six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual locations) of each tooth other than third molars
Gingival Index (GI)	Baseline	GI; from six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual locations) of each tooth other than third molars
IL-10 and IL-1β levels in GCF	Baseline	GCF samples were obtained from one interproximal site in each quadrant

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026